Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP.
Jachimowicz RD, Pieper L, Reinke S, Gontarewicz A, Plütschow A, Haverkamp H, Frauenfeld L, Fend F, Overkamp M, Jochims F, Thorns C, Leo Hansmann M, Möller P, Rosenwald A, Stein H, Reinhardt HC, Borchmann P, von Tresckow B, Engert A, Klapper W. Jachimowicz RD, et al. Among authors: haverkamp h. Haematologica. 2021 Jun 1;106(6):1684-1692. doi: 10.3324/haematol.2019.243287. Haematologica. 2021. PMID: 32381573 Free PMC article.
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP.
Jachimowicz RD, Klapper W, Glehr G, Müller H, Haverkamp H, Thorns C, Hansmann ML, Möller P, Stein H, Rehberg T, von Tresckow B, Reinhardt HC, Borchmann P, Chan FC, Spang R, Scott DW, Engert A, Steidl C, Altenbuchinger M, Rosenwald A. Jachimowicz RD, et al. Among authors: haverkamp h. Leukemia. 2021 Dec;35(12):3589-3593. doi: 10.1038/s41375-021-01314-1. Epub 2021 Jun 10. Leukemia. 2021. PMID: 34112956 Free PMC article. No abstract available.
Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A. Shimabukuro-Vornhagen A, et al. Among authors: haverkamp h. J Clin Oncol. 2005 Aug 20;23(24):5739-45. doi: 10.1200/JCO.2005.17.970. Epub 2005 Jul 11. J Clin Oncol. 2005. PMID: 16009944
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Borchmann P, et al. Among authors: haverkamp h. J Clin Oncol. 2011 Nov 10;29(32):4234-42. doi: 10.1200/JCO.2010.33.9549. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990399 Clinical Trial.
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group.
Bröckelmann PJ, Goergen H, Fuchs M, Kriz J, Semrau R, Baues C, Kobe C, Behringer K, Eichenauer DA, von Tresckow B, Klimm B, Halbsguth T, Wongso D, Plütschow A, Haverkamp H, Dietlein M, Eich HT, Stein H, Diehl V, Borchmann P, Engert A. Bröckelmann PJ, et al. Among authors: haverkamp h. Br J Haematol. 2015 Nov;171(4):547-56. doi: 10.1111/bjh.13646. Epub 2015 Aug 27. Br J Haematol. 2015. PMID: 26310520 Free article.
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A. Borchmann P, et al. Among authors: haverkamp h. Lancet Oncol. 2017 Apr;18(4):454-463. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22. Lancet Oncol. 2017. PMID: 28236583 Clinical Trial.
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).
Gillessen S, Hüttmann A, Vucinic V, Müller H, Plütschow A, Viardot A, Topp MS, Kobe C, Böll B, Eichenauer DA, Sasse S, Haverkamp H, Schmitz C, Borchmann S, Bröckelmann PJ, Heger JM, Fuchs M, Engert A, Borchmann P, von Tresckow B. Gillessen S, et al. Among authors: haverkamp h. Br J Haematol. 2022 Feb;196(3):606-616. doi: 10.1111/bjh.17878. Epub 2021 Nov 14. Br J Haematol. 2022. PMID: 34775591 Clinical Trial.
98 results